The Director, Market Access, reporting to the Vice President, Market Access, will be responsible for the design and implementation of market interventions and will play a leading role in increasing access to and adoption of new TB regimens in 25+ countries with high incidence of tuberculosis. Through market understanding and access strategies, the Director, Market Access will contribute to rapid and successful introduction and uptake of improved TB treatments, working at both a global and country level.
The position is very broad in scope, with involvement in both the pediatric and adult markets, both demand and supply side initiatives, both public health and the private sector markets, and building support for both adoption of new formulations of existing treatment regimens as well as support for patient access to new regimens. Market access at the TB Alliance includes all elements on the value chain including manufacturing, pricing, forecasting, procurement, and regulatory issues as well as technical adoption-related issues such as policy, market understanding, and diagnostics.
The opening is happening at an exciting time for new TB regimens. Phase 3 results for the REMox trial that would shorten treatment from 6 to 4 months are expected in early 2014. Additionally Phase 2b results on a PaMZ regimen are expected in Q4 2013, and a pediatric TB initiative began in 2013.
The individual right for this job will be motivated to “make a difference,” which is a pivotal reason why the individual wishes to join the TB Alliance.
The TB Alliance is an international product development partnership (PDP) created to accelerate the development and adoption of urgently needed new anti-tuberculosis (TB) drugs. As a not-for-profit organization, the TB Alliance functions through strategic relationships with pharmaceutical companies, academic institutions, research labs, multilateral institutions, and governmental agencies, and deploys preferred service providers for contract research. Based in New York City, the TB Alliance also operates a satellite office in Pretoria, South Africa.
The TB Alliance is preeminent in the TB drug development field and is pursuing faster, simpler treatments for all forms of TB through the innovative PDP business model that bridges the expertise and functionality of industry with academic and public sector interests to meet a major unmet global health need.
With an annual operating budget of approximately $60 million, the TB Alliance leads the advancement of the most comprehensive R&D portfolio of TB drug candidates in history. Currently, a portfolio of more than 20 projects spans from target validation to Phase III clinical development. Additionally, the TB Alliance drives efforts to ensure regulatory approval, country adoption of new regimens, and widespread availability of new drug regimens to patients.
Tuberculosis kills nearly 1.5 million each year. Yet, current treatments are antiquated, inadequate, and excessively burdensome. Long, demanding treatment schedules prove too much for many patients, leading to the emergence of multi- and extensively- drug-resistant TB (MDR-TB and XDR-TB), which are exponentially more expensive and difficult to treat.
For more information, please access the website: www.tballiance.org.
To apply for this position, send resumes and cover letters to email@example.com. Please include “Director, Market Access” in the Subject line.